Abstract
A series of amino acid ester prodrugs of the dual VEGFR-2/FGFR-1 kinase inhibitor 1 (BMS-540215) was prepared in an effort to improve the aqueous solubility and oral bioavailability of the parent compound. These prodrugs were evaluated for their ability to liberate parent drug 1 in in vitro and in vivo systems. The l-alanine prodrug 8 (also known as brivanib alaninate/BMS-582664) was selected as a development candidate and is presently in phase II clinical trials.
MeSH terms
-
Administration, Oral
-
Alanine / analogs & derivatives
-
Animals
-
Biological Availability
-
Carcinoma / drug therapy*
-
Cell Proliferation / drug effects
-
Clinical Trials, Phase II as Topic
-
Drug Design
-
Drug Evaluation, Preclinical
-
Humans
-
Intestines / drug effects
-
Liver / drug effects
-
Lung Neoplasms / drug therapy*
-
Mice
-
Microsomes / drug effects
-
Molecular Structure
-
Prodrugs / chemical synthesis
-
Prodrugs / chemistry
-
Prodrugs / pharmacology*
-
Protein Kinase Inhibitors / chemical synthesis
-
Protein Kinase Inhibitors / chemistry
-
Protein Kinase Inhibitors / pharmacology*
-
Pyrroles / chemical synthesis
-
Pyrroles / chemistry
-
Pyrroles / pharmacology*
-
Receptor, Fibroblast Growth Factor, Type 1 / antagonists & inhibitors*
-
Solubility
-
Stereoisomerism
-
Triazines / chemical synthesis
-
Triazines / chemistry
-
Triazines / pharmacology*
-
Vascular Endothelial Growth Factor Receptor-2 / antagonists & inhibitors*
-
Water / chemistry
-
Xenograft Model Antitumor Assays
Substances
-
Prodrugs
-
Protein Kinase Inhibitors
-
Pyrroles
-
Triazines
-
Water
-
brivanib
-
Receptor, Fibroblast Growth Factor, Type 1
-
Vascular Endothelial Growth Factor Receptor-2
-
Alanine